The Nipah Specter and its Prospects
Journal of Rapti Academy of Health Sciences · 07.04.2026 · 2 (2) · iv-v
DOI: 10.70027/jrahs138 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Rapti Academy of Health Sciences, online erschienen am 07.04.2026. Verfasst von Anup Pandeya. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Even though the world has moved on from the COVID-19 pandemic, the recent discovery of two Nipah virus (NiV) cases in West Bengal, India, has raised serious health concerns about the emergence of infectious diseases.1 NiV is a highly fatal zoonotic virus that causes severe disease characterized by acute respiratory illness and fatal encephalitis. It is classified as Biosafety Level 4 (BSL-4), for which no cure or vaccine has been developed so far.2 Thus, this virus is featured on the WHO research and development blueprint list of priority diseases due to its epidemic potential.3 There are two strains of NiV- the Malaysian strain (NiV-M) and the Bangladesh strain (NiV-B).4 The two individuals infected with NiV were medical professionals in West Bengal's Barasat city with the NiV-B, who were confirmed through Reverse Transcription Polymerase Chain Reaction (RT-PCR) and Enzyme-Linked Immunosorbent Assay (ELISA) testing.1 This highlights both advancements in rapid identification and persistent weaknesses in the healthcare system to develop further strategies to fight against these notorious viral infections.
Zitieren
APA
Pandeya, A. (2026). The Nipah Specter and its Prospects. Journal of Rapti Academy of Health Sciences, 2(2), iv-v. https://doi.org/10.70027/jrahs138
Vancouver
Pandeya A. The Nipah Specter and its Prospects. Journal of Rapti Academy of Health Sciences. 2026;2(2):iv-v. doi:10.70027/jrahs138
BibTeX
@article{Pandeya2026,
author = {Pandeya, Anup},
title = {The Nipah Specter and its Prospects},
journal = {Journal of Rapti Academy of Health Sciences},
year = {2026},
volume = {2},
number = {2},
pages = {iv--v},
doi = {10.70027/jrahs138}
}
EUVIMED